GENETIC MEDICINES AND INDIVIDUALIZED MANUFACTURING FOR EVERYONE (GIVE)
ID: ARPA-H-SOL-25-129Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)Washington, DC, 20005, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT (AN13)

Set Aside

No Set aside used (NONE)
Timeline
    Description

    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. This initiative aims to revolutionize the biomanufacturing of RNA-based genetic medicines by fostering innovations in automated RNA manufacturing and integrated quality control, ultimately enabling rapid, cost-effective, and localized production in non-GMP environments. Interested parties must submit solution summaries by December 19, 2025, with full proposals due by February 27, 2026, and are encouraged to participate in a Proposers’ Day on November 13, 2025, for further insights. For additional information, please refer to the program's website or contact the designated email address.

    Point(s) of Contact
    Files
    Title
    Posted
    The Advanced Research Projects Agency for Health (ARPA-H) has issued an Innovative Solutions Opening (ISO) for the "Genetic Medicines and Individualized Manufacturing For Everyone (GIVE)" program (ARPA-H-SOL-25-129). This initiative seeks to revolutionize biomanufacturing to enable rapid, affordable, and widespread access to genetic and personalized/individualized (P/I) medicines, particularly RNA-based therapies, for terminal, rare, and chronic diseases. The program envisions a distributed manufacturing network capable of producing GMP-quality genetic medicines in non-GMP environments like hospitals. GIVE is structured into two technical areas (TAs): Automated RNA Manufacturing (TA1) and Integrated Quality Control (TA2). The program spans 54 months over three phases, with a focus on developing highly automated, integrated, and digitally compliant systems for both manufacturing and quality control. Eligibility is open to all responsible sources, with an emphasis on U.S. entities, and proposals will be evaluated on scientific merit, proposer capabilities, contribution to the ARPA-H mission, and cost. Solution Summaries are due December 19, 2025, and Full Proposals by February 27, 2025.
    The ARPA-H GIVE Attachment A outlines the Solution Summary Template for proposals, detailing formatting and content requirements for federal grants. Submissions must be in English, with an 11-point font minimum (smaller for figures). Page limits are 10 pages for a single Technical Area (TA) or 12 for both TAs, excluding the Title Page and References. Key sections include a Title Page (with team, cost, and contact details), a one-page Concept Summary, a Proposed Work section (up to 6 or 8 pages depending on TA count), a one-page Innovation and Impact section, a one-page Team Organization and Capabilities section, and a one-page Basis of Estimate. The document provides clear guidance for structuring proposals to address technical areas, articulate innovative solutions, detail team capabilities, and present a comprehensive budget breakdown.
    The ARPA-H GIVE Attachment B1 outlines the comprehensive format and instructions for submitting full proposals. It details required components like the Title Page, Background, Technical Plan Overview, Technical Plan, Innovation and Impact, and Capabilities and Management Plan. The document specifies formatting requirements, including page limits (30 pages for single TA, 40 for both TAs) with certain sections excluded, such as the Title Page, Appendices, References, and Resumes. Proposals must address all program phases and relevant Technical Areas (TA1, TA2, or both) and include detailed technical approaches, challenges, and solutions. Appendices provide crucial information on Quality Target Product Profiles (QTPP) and Phase 2 and 3 product targets for various RNA formats, along with representative GMP Product Quality Attributes, emphasizing the need for comprehensive quality control and manufacturing plans.
    Attachment B2 outlines the full proposal format and instructions for an Alternative Approach to the ARPA-H GIVE program, focusing on Manufacturing (TA1) and Quality Control (TA2) solutions. Proposers must submit an integrated proposal addressing the Program Vision, demonstrating why their alternative approach is superior to the existing ISO. Proposals can target one or both TAs and must adhere to strict formatting guidelines, including page limits (30 pages for a single TA, 40 for both) and specific content sections like Background, Technical Plan Overview, Technical Plan, Innovation and Impact, and Capabilities and Management Plan. Excluded from page limits are the Title Page, Appendices (A-D), References, and Resumes. Appendices detail Quality Target Product Profiles (QTPP) and product targets for Phase 2 (Non-GMP) and Phase 3 (GMP), along with representative GMP product quality attributes, providing critical metrics for RNA-based products. The document emphasizes conciseness, specific examples, and adherence to evaluation criteria.
    ARPA-H GIVE's Attachment B2 outlines the full proposal format and instructions for an alternative approach to manufacturing (TA1) and quality control (TA2) solutions. Proposers must submit an integrated document addressing the Program Vision, demonstrating why their alternative is superior to the existing ISO approach. Proposals should not exceed 30 pages for a single TA or 40 pages for both, excluding the title page, references, resumes, and appendices. Key sections include Background, Technical Plan Overview, Technical Plan, Innovation and Impact, and Capabilities and Management Plan. The Technical Plan is central, requiring detailed tasks, metrics, milestones, and deliverables. Appendices A, B, C, and D provide templates for Quality Target Product Profiles (QTPP) and product quality attributes for Phase 2 and Phase 3, which must be completed by offerors. The document emphasizes conciseness, specific examples, and adherence to formatting guidelines to ensure proposals are reviewed.
    Attachment C, the Administrative & National Policy Requirements Document, is a critical component of federal government proposals, outlining essential administrative, policy, and compliance requirements. It mandates comprehensive disclosure of team member identification, including U.S. and non-U.S. entities, and requires senior/key personnel to submit Biographical Common Forms and Current and Pending (other) Support Common Forms to address potential conflicts of interest and commitment. The document also addresses Federally Funded Research and Development Center (FFRDC) participation, Organizational Conflicts of Interest (OCI) with specific disclosure and mitigation plan requirements, and detailed research security disclosures concerning malign foreign talent recruitment programs and foreign ownership or research execution. Furthermore, it requires information on the novelty of proposed work, intellectual property (IP) assertions and associated government rights, and details regarding Human Subjects Research (HSR) and Animal Subjects Research (ASR), including necessary approvals. Representations on unpaid delinquent tax liability or felony convictions, cybersecurity protocols for securing systems and managing Controlled Unclassified Information (CUI), and biosecurity plans addressing dangerous gain-of-function research and synthetic nucleic acid procurement are also required. The document emphasizes accuracy, completeness, and adherence to federal policies, with certifications against misrepresentation.
    The provided government file outlines the structure for a Task Description Document (TDD) and a Milestone Payment Schedule for federal government RFPs, grants, and state/local RFPs. The TDD details project tasks across a Base Period (Phase 1) and two Option Periods (Phases 2 and 3), broken down by technical area and individual tasks. Each task requires descriptions, responsible organizations, completion criteria (qualitative and quantitative metrics), and deliverables. The Milestone Payment Schedule links tasks to milestones with due dates, descriptions, exit criteria, deliverables, and associated payment values, including ARPA-H payments and performer cost-sharing. The document emphasizes clear, quantifiable criteria for tasks and milestones to track program progress and ensure verifiable outcomes.
    The document "ATTACHMENT E: GANTT Chart Sample" provides a template for a project schedule, likely for government RFPs, grants, or similar initiatives. It outlines a structured approach to project management using a GANTT chart format, detailing tasks and milestones with specific start and end dates over a multi-quarter timeline. Key features include Go/No-Go indicators for critical milestones, fractional numbering for duration, and visual representations for tasks (blue bars) and milestones (triangles). The template emphasizes the importance of clear task titles, milestone descriptions with associated exit criteria, and a flexible timeline to represent project progression. It serves as a representative example, not a fixed schedule, allowing for adaptation to various project needs while ensuring all critical elements are tracked.
    This government file, "ATTACHMENT F: Cost Proposal Spreadsheet," provides a comprehensive template for submitting cost proposals for multi-party or prime/sub government projects. It outlines detailed instructions for prime performers, sub-performers, and team members to ensure consistent and thorough cost reporting across all project phases (Phase I, II, and III). Key components include direct labor costs by category and technical area, sub-performer and team member costs, sub-contractor and consultant costs, and other direct costs such as materials, equipment, and travel. The spreadsheet also features sections for profit, cost share, and a detailed breakdown of costs by task/milestone. It emphasizes the need for separate spreadsheets from each entity, fully burdened labor rates, and clear explanations for cost share arrangements, assuming a March 1, 2026, project start date.
    The document, "ATTACHMENT G: COST PROPOSAL NARRATIVE," outlines the requirements for submitting a cost proposal for government contracts, grants, or RFPs. It details the necessary components of a written narrative that substantiates price/cost drivers, in addition to a cost spreadsheet. Proposers must include an index for all cost details and supplemental information. Key sections of the proposal include organizational information, technical and administrative points of contact, period and place of performance, and team member details. The document specifies nine critical elements for price/cost details: level of effort, materials, equipment purchases, travel, other direct costs (ODCs), cost sharing, consultant costs, team member costs, and a value analysis explaining the return on investment for taxpayer dollars. Each section requires detailed breakdowns, supporting documentation, and assumptions to justify proposed costs, including indirect costs and profit/cost share. The proposal must adhere to specific formatting guidelines and remain valid for at least 120 days. This comprehensive guide ensures transparency and accountability in government procurement.
    ARPA-H-SOL-25-129, GIVE, is an Innovative Solutions Opening (ISO) focused on Genetic Medicines and Individualized Manufacturing for Everyone (GIVE). This amendment outlines key changes to dates, including a Proposers’ Day on November 13, 2025, a question submission deadline of February 13, 2026, and full proposals due on February 27, 2026. The program seeks to revolutionize biomanufacturing of RNA-based genetic medicines, enabling rapid, cost-effective, and localized production in non-GMP environments like hospitals. It comprises two technical areas (TAs): Automated RNA Manufacturing (TA1) and Integrated Quality Control (TA2), both requiring a 54-month, three-phase development. Offerors must submit quality target product profiles for three distinct RNA products and address regulatory assessment, business models, and technoeconomic feasibility. The solicitation also welcomes alternative approaches that meet the GIVE vision.
    Lifecycle
    Similar Opportunities
    Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the "Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)" program. This initiative aims to accelerate the development of innovative precision genetic medicines (PGMs) to treat hereditary rare diseases, focusing on creating integrated platforms that address technical and real-world challenges in genetic medicine. Proposals must include a solution summary, a PowerPoint presentation, and a detailed Gantt chart, with key deadlines set for October 31, 2025, for solution summaries and December 22, 2025, for PowerPoint submissions. Interested parties can contact the THRIVE Program at THRIVE@arpa-h.gov for further information.
    Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting innovative solutions aimed at enhancing the healthspan and health outcomes of Americans by focusing on proactive health measures. The Proactive Health Office (PHO) seeks proposals that address population-level improvements in disease prevention, early detection methods, and system-level innovations for effective health delivery, emphasizing revolutionary advances rather than incremental improvements. This opportunity is critical for fostering advancements in public health and requires adherence to specific administrative and national policy guidelines, including intellectual property rights and research security measures. Interested parties must submit a Solution Summary by March 5, 2029, and can find further details and submission links at https://solutions.arpa-h.gov, with inquiries directed to the same site.
    Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO). This opportunity invites submissions that address systemic challenges in healthcare and public health by leveraging innovative technologies to improve care quality, efficacy, and accessibility. Proposals will be evaluated based on scientific merit, alignment with ARPA-H's mission, proposer capabilities, and cost, with a focus on open-source intellectual property and compliance with research regulations. Interested parties must submit solution summaries and proposals via the designated ARPA-H portal, with the closing date for submissions set for March 5, 2029. For further inquiries, proposers can reach out through the same portal.
    Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO). This initiative aims to gather innovative solutions that address future healthcare challenges, focusing on groundbreaking research in areas such as maternal/fetal medicine, genetic therapies, chronic diseases, and mental health, while excluding proposals for incremental advances or clinical trials. Proposers are required to submit a Solution Summary for initial feedback, followed by a detailed proposal that adheres to updated administrative and national policy requirements, including compliance with ethical research guidelines and research security disclosures. Interested parties should submit their proposals via the designated ARPA-H portal, with specific deadlines and further details available through the provided links.
    Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) under the Scalable Solutions Office (SSO). This initiative aims to develop innovative solutions that enhance healthcare access, affordability, and distribution, particularly in underserved communities, while addressing challenges in biomanufacturing and health technology distribution. The solicitation is open until March 5, 2029, and encourages submissions from academia, non-profits, and for-profit entities, with multiple awards anticipated as Other Transactions. Interested parties must submit a Solution Summary for initial feedback before proceeding with a full proposal, adhering to strict guidelines on intellectual property, research security, and cost proposal requirements. For further details, proposers can reach out through the designated submission portals and must ensure compliance with the updated administrative and national policy requirements outlined in the solicitation documents.
    BioStabilization Systems (BoSS)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is seeking proposals for the BioStabilization Systems (BoSS) program aimed at revolutionizing the stabilization, manufacturing, and distribution of live cell-based therapies. The program addresses the critical challenge of ultra-cold storage requirements for advanced cell and gene therapies by developing bioprocessing systems that enable the production of thermally stable cells, thereby enhancing the efficiency and resilience of biologics distribution. Interested parties can submit Solution Summaries for consideration as either Performer teams or Independent Verification and Validation (IV&V) partners, with deadlines set for February 19, 2026, and April 17, 2026, respectively. For more information, including submission guidelines and program details, please visit the ARPA-H website or refer to the attached documents.
    Autonomous Interventions and Robotics (AIR) Advanced Research Projects Agency for Health (ARPA-H)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is seeking proposals for its Autonomous Interventions and Robotics (AIR) program, which aims to advance autonomous robotic surgery technologies. This initiative focuses on two technical areas: Autonomous Endovascular Robotics, which includes developing robotic systems for endovascular procedures and creating a simulation environment, and Microbots, which targets the development of untethered, autonomous microbots for various interventional procedures. The program is structured over a five-year timeline with specific phases and milestones, emphasizing collaboration with the FDA for regulatory approval. Interested parties are encouraged to attend a Proposers’ Day on December 16, 2025, in Washington, DC, to learn more about the program and network with potential collaborators. For further inquiries, contact the AIR Program at AIR@ARPA-H.GOV.
    Autonomous Interventions and Robotics (AIR) Advanced Research Projects Agency for Health (ARPA-H)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Autonomous Interventions and Robotics (AIR) program, aimed at advancing autonomous robotic surgery technologies. This initiative focuses on two key technical areas: autonomous endovascular robotics, which includes developing systems for procedures such as thrombectomy and embolization, and the creation of untethered microbots for various clinical applications. The program is critical for enhancing medical interventions and is structured over a five-year timeline, with specific milestones for development and testing phases. Interested parties, including universities, non-profits, and businesses, must submit their proposals by March 30, 2026, with a preliminary Solution Summary due by January 26, 2026. For further inquiries, contact the AIR Program at AIR@ARPA-H.GOV.
    EVIDENT (Evidence-Based Validation & Innovation for Rapid Therapeutics)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is initiating the Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) initiative to fund innovative solutions that align with HHS and ARPA-H objectives. This initiative aims to efficiently support research and development in the field of behavioral health, particularly focusing on rapid therapeutic innovations. The Proposers’ Day, scheduled for December 10, 2025, will provide an opportunity for interested parties to learn more about the technical areas of the EVIDENT initiative and to engage with ARPA-H and Advanced Technology International (ATI). For additional information and registration details, interested parties are encouraged to refer to the provided links.
    Special Notice for BioStabilization Systems (BoSS)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is announcing a Special Notice for the BioStabilization Systems (BoSS) program, with a Proposers’ Day scheduled for January 29, 2026. This initiative aims to revolutionize the storage and transport of biological medicines by developing technologies that eliminate the need for ultra-cold conditions, and it seeks performer teams for breakthrough cell stabilization technologies and bioprocessing solutions, as well as an Independent Verification and Validation (IV&V) partner. The program is structured in three phases over four years, culminating in the transition of successful technologies to commercial partners, and encourages collaboration among teams. Interested parties can find more information and registration details on the ARPA-H website and should direct inquiries to the provided contact email, although it is noted that the email address should not be used for direct communication.